Friday, 23 October 2026

diarioempresas

IBEX 3518.989,80▲ +0,40%EuroStoxx 506068,22▼ -0,31%S&P 5007627,22▼ -0,47%€/$1,1196▼ -0,23%Brent111,57▲ +2,68%Bitcoin72.728▲ +0,36%
Breaking

GEICAM

Latest GEICAM news

1 article

Illustrative image: a laboratory glass vial on a wooden table at sunset, with long shadows.

Kisqali Reduces Risk of Death by 19.1% in Early Breast Cancer

Kisqali from Novartis reduces the risk of death by 19.1% in high-risk early HR+/HER2- breast cancer compared to endocrine therapy alone, according to the NATALEE trial.